Two draft guidances issued together late last month seek to increase both clinical trial efficiency and the amount of information that is available about a drug’s safety and benefits. The two draft guidances address, respectively, adaptive designs and master protocols. This blog post discusses FDA’s recommendations for adaptive designs; master protocols will be addressed in a subsequent blog post.
An adaptive design is a “clinical trial design that allows for prospectively planned modifications to one or more aspects of the design based on the accumulating data from ...
Blog Editors
Recent Updates
- Listen: DOJ’s Bulk Sensitive Data Transfer Rule: Key Insights for Health Care Compliance Teams – Diagnosing Health Care
- FDA Launches Home Innovation Challenge for Medical Device Technologies
- FDA Meeting Invites Stakeholders to Weigh in on Dietary Supplement Ingredients
- California Targeted in House Committee Investigation of Hospice Fraud
- HHS OIG Issues Favorable Advisory Opinion Regarding Surgical Supply Discounts to Ambulatory Surgery Centers in Exchange for Software Purchases